J&J, Bristol Myers lose challenges to US drug price negotiation program A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb (BMY.N) and Johnson & Johnson (JNJ.N) to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.
The lawsuit, opens new tab, filed in New Jersey federal court by Ann Lewandowski, a healthcare policy and advocacy director, accuses Johnson & Johnson of breaching its duty under the federal Employee Retirement Income Security Act of 1974 (ERISA) to prudently manage employee benefit plans.
The plans, for example, pay $1,629 for a 90-pill prescription of HIV antiviral drug abacavir-lamivudine that costs pharmacies about $180, according to the complaint. And while prescriptions of teriflunomide, used to treat multiple sclerosis, typically cost no more than $77 out of pocket, Johnson & Johnson's health plans pay $10,200, the lawsuit claims.
... rejecting their argument that it was an illegal taking of their property.
In short, defendants are not taking drugs from plaintiffs," Quraishi wrote, adding that they were free to stop participating in Medicare if they did not want to negotiate.
Pharmaceutical manufacturers can withdraw their products from Medicare and Medicaid formularies at any point during the negotiation process with the U.S. Centers for Medicare and Medicaid Service (CMS). If a manufacturer doesn't agree with CMS's final offer, they can choose to sell their products at the CMS price, sell at their preferred price and pay an excise tax, or withdraw their products.
Several have said they were essentially （1）forced to participate or （2） otherwise face steep penalties or （3）withdrawal from the Medicare and Medicaid markets.
J&J, Bristol Myers lose challenges to US drug price negotiation program
A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb (BMY.N) and Johnson & Johnson (JNJ.N) to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.
UNH，HUM也是每次大选暴跌一次。过后就没事啦。
只许百姓放火，不许州官点灯？这个世界反了么？
我父母的胰岛素，只有两个牌子产，他们的私人医疗保险只保一个牌子，不保另一个牌子。如果每年要是他们换保险，就要去医生那里去换胰岛素的牌子，因为可能新保险只保另一个牌子而不保前一个牌子。
这不就是私人保险公司和药厂谈判的成果？给我点便宜，我就只用你一个牌子。政府也是经济体，为什么不能谈判？
现在J&J和Ｂ＆Ｍ是说，你们ｍｅｄｉｃａｒｅ要保我们这两个药，不能play us against each other，因为你们是政府政府不能ｐｉｃｋ ｗｉｎｎｅｒａｎｄｌｏｓｅｒ，不能强迫我们降价，违宪！违宪！
BS ! 政府造飞机航天器，都是用的最便宜的合同工！
这个被认为违反了第一宪法修正案，第五宪法修正案和第八宪法修正案。最后可能还得打到最高法院。
当然我也没有看案件细节。
https://www.reuters.com/legal/litigation/jj-faces-class-action-over-employees-prescription-drug-costs-2024-02-05/
The lawsuit, opens new tab, filed in New Jersey federal court by Ann Lewandowski, a healthcare policy and advocacy director, accuses Johnson & Johnson of breaching its duty under the federal Employee Retirement Income Security Act of 1974 (ERISA) to prudently manage employee benefit plans.
The plans, for example, pay $1,629 for a 90-pill prescription of HIV antiviral drug abacavir-lamivudine that costs pharmacies about $180, according to the complaint. And while prescriptions of teriflunomide, used to treat multiple sclerosis, typically cost no more than $77 out of pocket, Johnson & Johnson's health plans pay $10,200, the lawsuit claims.
https://uscode.house.gov/view.xhtml?req=(title:26%20section:5000D%20edition:prelim)
https://rsmus.com/insights/tax-alerts/2023/irs-issues-proposed-regulations-5000d-excise-tax.html
看看这些罚款，没法让我相信这是一个公平的价格谈判。 民间商务谈判，价格不合适，大不了这个生意不做了。
参加Medicare是自愿的， 这里是法官判的理由。
... rejecting their argument that it was an illegal taking of their property.
In short, defendants are not taking drugs from plaintiffs," Quraishi wrote, adding that they were free to stop participating in Medicare if they did not want to negotiate.Medicare可以要求所有OECD国家医保集采价格的最低价格，也许上浮一个固定的百分点。
但现在CMS的官员坚持要自己的定价权，不知在搞什么鬼。
不知道这些公司还能存活下来吗？
Eliquis brought Bristol Myers about $8.52 billion in U.S. sales last year, while J&J recorded $2.36 billion in Xarelto sales.
JNJ annual sales 85B, BMY 45B. not going to kill these two compaies. 退出肯定有影响，但在medicare 之外还可以卖，只是量每那么大，平常利润顶多20%，revenue 减半以后铁定亏损，裁人是起码的。
Pharmaceutical manufacturers can withdraw their products from Medicare and Medicaid formularies at any point during the negotiation process with the U.S. Centers for Medicare and Medicaid Service (CMS). If a manufacturer doesn't agree with CMS's final offer, they can choose to sell their products at the CMS price, sell at their preferred price and pay an excise tax, or withdraw their products.
说以不是所有的药都一起退出。
只是对楼主老是有选择性的发布负面消息有点看不下去， 还是那种只说他想看到的一半那种。
https://www.cnn.com/2024/02/01/politics/medicare-drug-price-negotiations-initial-offers/index.html
Several have said they were essentially （1）forced to participate or （2） otherwise face steep penalties or （3）withdrawal from the Medicare and Medicaid markets.
不降价就不保你的药，难道私人医疗保险不是这样的吗？私人医疗保险也不是所有的药都保。
只是正好对这个议题有点兴趣
GREED WATCH: Bristol Myers Squibb Brought In More Than $45 Billion In 2023
https://www.protectourcare.org/greed-watch-bristol-myers-squibb-brought-in-more-than-45-billion-in-2023/
2019年FDC已批准Eliquis仿制药。 BMY使用各种策略将其专利延长至2026年。为什么？ 药品贡献了其2/3的利润。 Eliquis是Medicare处方中的NO.1药物，受益人数最多的会员 (3.5 million)。虽然Medicare花费最多的不是Eliquis，而是两种癌症药物，每种药物只惠及不到3万名会员。
Eiquis is at about $600 a month. Many Medicare Advantage plans cover it with only $5 co-pay but pay the full cost of the drug.
2024 Medicar Plan D allowance is 5030. Once over that you enter the donut hole (coverage gap)
At $600 a month, a patient even ONLY needs Eliquis (hardly likely), would go into donut hole by August.
8x600 = 4800.
一旦进入 Donut Hole，患者将承担25%的药品费用加上配药费（由配药的药房收取）。
Basically BMY is a 吸血者. It is about time to do something to stop the sleazy tactics big pharma used, i.e. using loophole to extend patent.
有没有人查一下腐败问题？
大家就都是奴隶。
such as changed some applicable usages, component modification. Nothing to do with FDA.
但是我们可以允许政府榨取一些医药公司的利润！